TriangleAlectinib (NCT04302025)
Alectinib trial for Non-small Cell Lung Cancer (NCT04302025). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, surgically removable KRAS G12C-mutated non-small-cell lung cancer, stages IB–IIIA or selected IIIB. Other biomarker groups are closed.
The idea: oral divarasib blocks signaling from mutant KRAS. Patients receive up to eight weeks before surgery. Afterwards, PD-L1-negative patients may continue divarasib with or without preceding chemotherapy; PD-L1-positive patients may receive chemotherapy then atezolizumab, or standard care. Researchers assess serious side effects and whether treatment delays surgery. Treatment after surgery depends on eligibility and response.
This phase 2 study plans 99 patients. Genentech sponsors twenty-three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.